Ezlife Bio Inc.
EZLife Bio Inc. is crafting the future of genetic testing. Using the novel EFIRM (electric field induced release and measurement) platform, EZLife Bio is
Listen to a new podcast interview of Dr. Charles Strom, one of our close collaborators, as he discusses EFIRM and the future of medicine in the United States!
https://www.bloomberg.com/news/audio/2022-06-17/charles-strom-on-the-diagnostics-industry-podcast
07/02/2022
Read about the latest applications for EFIRM in COVID-19 diagnostics and agriculture!
http://ezlife.bio/2022/02/07/new-efirm-publications.html
Latest EFIRM Applications (COVID-19 and Agriculture) In view of the global COVID-19 pandemic, the EFIRM technology has been on the cutting edge of helping work towards the resolution of the crisis. Read about a recent application of the EFIRM technology for mRNA COVID-19 vaccinations in saliva in the respected Journal of Immunology:
04/07/2021
Read our latest publication: EFIRM was used for applications in lung cancer treatment monitoring!
https://www.mdpi.com/2072-6694/13/13/3342
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma Background: We assessed whether serial ctDNA monitoring of plasma and saliva predicts response and resistance to osimertinib in EGFR-mutant lung adenocarcinoma. Three ctDNA technologies—blood-based droplet-digital PCR (ddPCR), next-generation sequencing (NGS), and saliva-based EFIRM liquid biopsy ...